Flexible dose of semaglutide reduces early discontinuation while maintaining comparable outcomes in obese patients: FLEX-SEMA 2.4 mg, an Italian real-world study.

Key Result

Flexible dosing of semaglutide reduces early discontinuation and maintains comparable efficacy in obese patients in real-world clinical practice.

Key Points

• The study aims to evaluate the impact of flexible dosing of semaglutide on treatment adherence and outcomes in obese patients.
• Conducted a real-world analysis of semaglutide use in clinical settings.
• Assessed patient outcomes related to flexible dosing patterns.
• Evaluated rates of treatment discontinuation among patients.
• Flexible dosing of semaglutide led to reduced early discontinuation rates.
• Efficacy outcomes of treatment remained comparable despite flexible dosing.
• Patients maintained weight loss benefits over the treatment period.